Guardant Health, Inc. news
Barcelona-based testing service will advance cancer research and enable clinicians to personalize treatments more accurately and quickly for patients with late-stage cancer
PALO ALTO, Calif. & BARCELONA, Spain--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, today announced that the first blood-based cancer testing servi
- Highly sensitive Shield test offers convenient screening method that can be completed with simple blood draw, helping overcome barriers to compliance
- Test demonstrated sensitivity of 91% in colorectal cancer and 20% in advanced adenoma detection with specificity of 92% in validation studies
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the availability of Shield™, the compan
- Partnership will Make Guardant Health Cancer Tests Available to Over 250 Million Patients with a Record in Epic
- Integration Will Simplify the Process for Clinicians to Order Tests and Access Results Directly in the Patient Record
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with Epic, the nation’s most widely used comprehensive health record, to integrate t
Lawsuit is Seen as an Attempt to Stifle Competition and Retaliate Against Guardant Health for Registering Concerns About the Antitrust Implications of Illumina’s Acquisition of Grail
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today provided the following statement regarding a lawsuit filed by Illumina that seeks to challenge Guardant Health’s ownership and authorship of a portion of its intellectual pro
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for Guardant360 TissueNext™ under the existing local coverage determination (LCD) (MolDX: Next-Generation Sequencing for Solid Tumors). Guardant360 TissueNext is the company’s first tissue-based test to help oncologists identif